By Fineline Cube 
ProBio, a subsidiary of GenScript Biotech Corporation (HKG: 1548), and China‑based Immunofoco have inked a strategic cooperation agreement to jointly commercialise cell‑and‑gene‑therapy (CGT) products. The partnership extends their proven early‑clinical collaboration into full‑scale CDMO services, positioning both firms to accelerate the global rollout of next‑generation CGT drugs.
What the Deal Covers
- Integrated Manufacturing – ProBio will supply end‑to‑end GMP production, from process development to commercial scale.
- Quality & Compliance – Leveraging ProBio’s robust quality‑system framework, the alliance will uphold the highest regulatory standards across all stages of CGT development.
- Commercial Momentum – Immunofoco gains access to ProBio’s manufacturing network, enabling rapid product launch and market penetration.
Strategic Significance
- Supply‑Chain Resilience – The tie‑up mitigates the current bottleneck in CGT production, a critical need as global demand surges.
- Innovation Acceleration – By aligning clinical and commercial pipelines, the partnership promises shorter time‑to‑market for breakthrough therapies.
- Global Reach – With ProBio’s established international footprint, Immunofoco’s therapies can be distributed worldwide, supporting the global CGT ecosystem.-Fineline Info & Tech